关注
Niki Gavrielatou
Niki Gavrielatou
在 yale.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Biomarkers for immunotherapy response in head and neck cancer
N Gavrielatou, S Doumas, P Economopoulou, PG Foukas, A Psyrri
Cancer treatment reviews 84, 101977, 2020
2002020
Patterns of response to immune checkpoint inhibitors in association with genomic and clinical features in patients with head and neck squamous cell carcinoma (HNSCC)
P Economopoulou, M Anastasiou, G Papaxoinis, N Spathas, A Spathis, ...
Cancers 13 (2), 286, 2021
242021
Discovery of biomarkers of resistance to immune checkpoint blockade in NSCLC using high-plex digital spatial profiling
M Moutafi, S Martinez-Morilla, P Divakar, I Vathiotis, N Gavrielatou, ...
Journal of Thoracic Oncology 17 (8), 991-1001, 2022
202022
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer
MK Moutafi, M Molero, SM Morilla, J Baena, IA Vathiotis, N Gavrielatou, ...
Journal for immunotherapy of cancer 10 (8), 2022
202022
Association of PD-1/PD-L1 co-location with immunotherapy outcomes in non–small cell lung cancer
N Gavrielatou, Y Liu, I Vathiotis, J Zugazagoitia, TN Aung, S Shafi, ...
Clinical Cancer Research 28 (2), 360-367, 2022
182022
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms
TN Aung, S Shafi, JS Wilmott, S Nourmohammadi, I Vathiotis, ...
EBioMedicine 82, 2022
162022
HER2 aberrations in non-small cell lung cancer: From pathophysiology to targeted therapy
IA Vathiotis, A Charpidou, N Gavrielatou, KN Syrigos
Pharmaceuticals 14 (12), 1300, 2021
132021
Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
P Economopoulou, I Kotsantis, G Papaxoinis, N Gavrielatou, ...
Oral Oncology 111, 105013, 2020
122020
Spatial characterization and quantification of CD40 expression across cancer types
KM Bates, I Vathiotis, T MacNeil, FS Ahmed, TN Aung, Y Katlinskaya, ...
BMC cancer 23 (1), 220, 2023
102023
Development of an immunohistochemical assay for Siglec-15
S Shafi, TN Aung, C Robbins, J Zugazagoitia, I Vathiotis, N Gavrielatou, ...
Laboratory Investigation 102 (7), 771-778, 2022
102022
PD-L1 expression scoring: noninterchangeable, noninterpretable, neither, or both
N Gavrielatou, S Shafi, P Gaule, DL Rimm
JNCI: Journal of the National Cancer Institute 113 (12), 1613-1614, 2021
102021
The role of B cells in head and neck cancer
N Gavrielatou, I Vathiotis, P Economopoulou, A Psyrri
Cancers 13 (21), 5383, 2021
102021
Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC)
P Economopoulou, A Spathis, I Kotsantis, E Maratou, M Anastasiou, ...
Oral Oncology 139, 106358, 2023
92023
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer
S Shafi, TN Aung, V Xirou, N Gavrielatou, IA Vathiotis, A Fernandez, ...
Laboratory Investigation 102 (10), 1143-1149, 2022
92022
Programmed death-ligand 1 and programmed death-ligand 2 mRNAs measured using closed-system quantitative real-time polymerase chain reaction are associated with outcome and high …
AI Fernandez, N Gavrielatou, L McCann, S Shafi, MK Moutafi, ...
Journal of Thoracic Oncology 17 (9), 1078-1085, 2022
92022
Molecular correlates of response to preoperative olaparib alone or with cisplatin or with durvalumab in head and neck squamous cell carcinoma (HNSCC): A Hellenic Cooperative …
A Psyrri, G Papaxoinis, N Gavrielatou, M Gkotzamanidou, ...
Journal of Clinical Oncology 38 (15_suppl), 6556-6556, 2020
82020
Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma
N Gavrielatou, I Vathiotis, TN Aung, S Shafi, S Burela, AI Fernandez, ...
Cancer Research Communications 3 (4), 558-563, 2023
72023
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma
N Gavrielatou, E Fortis, A Spathis, M Anastasiou, P Economopoulou, ...
Annals of Oncology 35 (4), 340-350, 2024
62024
Blood-based testing of mutations in patients with head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
F Fostira, P Oikonomopoulou, A Kladi, D Edelstein, K Stieler, D Heim, ...
Annals of Oncology 30, v469, 2019
62019
Phase II window study of olaparib alone or with cisplatin or durvalumab in operable head and neck cancer
M Moutafi, GA Koliou, G Papaxoinis, P Economopoulou, I Kotsantis, ...
Cancer Research Communications 3 (8), 1514-1523, 2023
32023
系统目前无法执行此操作,请稍后再试。
文章 1–20